In this Phase 2b double-blind , placebo-controlled study , treatment-naive adults with HCV genotype 1 ( N = 365 ) or 4 ( N = 30 ) infection were randomly assigned ( 2:2:1 ) to daclatasvir 20mg or 60mg , or placebo once daily plus weekly peginterferon-alfa-2a and twice-daily ribavirin .